Condition

HR Positive

ClinicalTrials.gov condition label

Clinical trials4
Recruiting1
Common interventions12
Lead sponsors shown3

Clinical trials

4 shown
PRE-ISPY Phase I/II Oncology Platform ProgramNCT05868226 · 2023-02-15
RECRUITING
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdNCT07683754 · 2026-09-04
NOT_YET_RECRUITING
Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibNCT07428018 · 2026-04-30
NOT_YET_RECRUITING
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerNCT04602117 · 2021-07-28
WITHDRAWN

Trial status mix

NOT_YET_RECRUITING2
RECRUITING1
WITHDRAWN1

Phase mix

PHASE12
PHASE22
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.